CLIA validated, FDA EUA authorized Test performed in a high throughput, high complexity Testing Lab
Avellino Lab USA, Inc. Is a global leader in gene therapy and molecular diagnostics and is at the forefront of precision medicine for eye care. The company is pioneering CRISPR gene editing to manage and potentially cure inherited diseases. Beyond the Avellino CoV2 test, Avellino recently launched AvaGen, the world's first DNA test to confirm the presence of genetic indicators that are positively associated with corneal dystrophies and keratoconus genetic risk factors. Avellino is headquartered in Sillicon Valley, California, with operations in Korea, Japan, China, and the UK
A non-invasive genetic test to identify the coronavirus
The Avellino SARS-CoV-2/COVID-19 Test (AvellinoCoV2) is a non-invasive, swab based test used to detect the SARS-CoV-2 virus, a strong indicator of the patient having the COVID-19 disease. A positive result generally indicates an active infection, while a negative result should not be used as the sole basis for treatment or other patient management decisions. All results, whether positive or negative, must be combined with clinical observations, patient history, and epidemiological information for a proper medical diagnosis. AvellinoCoV2 was developed by Avellino Lab USA, Inc., in its CLIA-qualified lab and is authorized by the FDA under the Emergency Use Authorization.